Guava Technologies, Inc. has launched a new and enhanced version of its Guava RapidQuant? IgG Antibody Quantification Assays for mouse and human antibodies. Faster and easier than the average enzyme-linked immunosorbent assay (ELISA), the traditional approach for antibody quantification, RapidQuant Assays help users select of optimal clones from hybridoma screens.
According to David King, VP R&D and Operations, Guava Technologies, these mix-and-read, bead-based assays were developed with users in mind. "We wanted to give scientists an assay that almost ran itself," said David. "The protocol is basically three simple steps; we eliminated the time-consuming sample preparation and washes common with many ELISAs."
Users are quickly adopting the assays as critical tools for antibody research: "The RapidQuant IgG Assay expands our toolbox for differentiating monoclonal antibody cultures and is an essential tool when sub-cloning to obtain higher antibody secretors," said Dr. John Kenney, President, Antibody Solutions, Mountain View, California, USA.
Results from RapidQuant Assay are read on a plate-based benchtop flow cytometer, such as the Guava EasyCyte? Plus System, and are equivalent to those obtained with traditional ELISAs.
Entirely new, the assay-specific RapidQuant Software gives users easy and complete data acquisition and analysis capabilities in a single program. Highly intuitive, it leads users directly to results while also offering customisable options for flexibility. And, assay processes are simplified with easy set-up, straightforward data acquisition, automatic analysis, and extensive data management options.
Product directory
